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Abstract
Aptamers are valuable tools for studying numerous aspects of
biological processes, opening up new experimental opportunities
to analyse the function of a wide range of cellular molecules.
Functional RNA molecules can be rapidly selected in vitro from
complex combinatorial mixtures of different sequences. Recently,
it was shown that in vitro selection processes can be automated:
the first generation selection robots will soon mean aptamers for
several targets can be isolated in parallel within days rather than
weeks. Aptamers not only exhibit highly specific molecular
recognition properties but are also able to modulate the function
of their cognate targets in a highly specific manner by agonistic or
antagonistic mechanisms. These properties prompted the devel-
opment of novel technologies to exploit the use of aptamers to
modulate distinct functions of biological targets. Recent con-
trolled expression of aptamers inside cells demonstrated their
impressive potential as rapidly generated intracellular inhibitors of
biomolecules. Intracellularly applied aptamers are also called
‘intramers’. Here we discuss recent developments and strategies for
intramer-based technologies that have the potential to greatly
facilitate characterisation of unknown protein functions in the
context of their natural expression status in vivo. Thus, intramer-
based technologies offer many promising applications in func-
tional genomics, proteomics and drug discovery. ß 2001 Elsevier
Science Ltd. All rights reserved.
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1. Introduction
In recent years, sequencing the genomes of individual
organisms has provided invaluable insights into the ge-
nomic structure of assorted cells and organisms in di¡er-
ent developmental or pathogenic states [1^6]. The e¡orts
of the various genome-wide sequencing projects have al-
ready led to the accumulation of an immense £ood of
data, emphasising the urgent need to develop new strat-
egies in drug target discovery and novel therapeutic con-
cepts [7,8]. The challenge of functional genomics and pro-
teomics, therefore, is to translate sequencing data into a
precise understanding of how genes, proteins, metabolites
and all the other molecules making up a cell are intercon-
nected and function in normal and diseased states, and to
develop techniques that facilitate rapid identi¢cation of
agonistic and antagonistic inhibitors [9].
2. Functional analyses of intracellular proteins
Considerable progress has been achieved in identifying
possible molecular causes for the onset of certain diseases.
Nevertheless, it remains di⁄cult to elucidate the function
of a protein based solely on knowing the gene that en-
codes it. In classical reverse genetics speci¢c genes are
mutated or completely inactivated by so-called knock-
out strategies, and the resulting phenotypes of the organ-
ism or cell can be characterised [10]. In higher eukaryotes,
this may be facilitated by regulated expression techniques
such as the Tet repressor system [11,12]. In its simplest
form, fusion proteins comprising the bacterial tetracycline
repressor (tetR) and transcriptional activator or repressor
domains bind to tetR DNA binding site(s) (tetO) adjacent
to a minimal promoter element following removal of tet-
racycline. This allows genes to be turned on or o¡ in a
targeted fashion. Alternatively, TetR mutants (rtT), which
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only bind to tetO in the presence of tetracycline, allow a
controlled induction of genes or their mutated versions
simply as a function of the tetracycline concentration [13].
Especially in diploid organisms, however, the generation
and expression of mutated genes is often painstaking and
identi¢cation of recessive phenotypes might be possible
only after analysis of the F2 generation. Therefore, genetic
knock-down technologies such as antisense, ribozymes and
RNAi were developed to allow the inactivation of genes
without directly manipulating the gene of interest [14,15].
While being extremely successful and increasingly used to
assess the function of genes, all these approaches share the
drawback that they alter the genetic information of an
organism and, in most cases, the expression pattern of
other genes in a somewhat unpredictable fashion. As a
consequence, it can be di⁄cult to interpret the biological
data and to reach reliable conclusions about the function
of the targeted molecule. For example, knocking out a
gene says nothing about which part or domain of the
protein is important for its function. Also these techniques
do not normally indicate whether a target quali¢es for
inhibition by agonistic or antagonistic mechanisms. There-
fore, approaches delivering alternative information about
the function of a protein by inactivating it directly within
its natural compartment are becoming increasingly impor-
tant.
Most inhibitors or modulators currently used as tools in
biomedical research, or indeed as pharmaceutical drugs,
are based on membrane-permeable small organic mole-
cules [16,17]. While being ideally suited for these purposes,
their initial identi¢cation by screening compound libraries
containing thousands of molecules is long and tedious.
Considering the multitude of potential targets now arising
from genome and proteome research, the capacity of high-
throughput screens is still too limited to rapidly generate
enough inhibitors for functional in vivo characterisation of
the huge numbers of potential targets.
3. Protein-based intracellular e¡ectors
Such limitations may be overcome by using antibody-,
protein-, or peptide-based large molecular e¡ectors to
modulate intracellular processes. These highly speci¢c
antigen binding protein derivatives can be isolated rela-
tively easily for large numbers of proteins by combinato-
rial methods such as phage [18] and ribosome display
[19,20]. Intracellular application of antibodies, however,
poses a major hurdle due to the paucity of molecules
that function in eukaryotic cells, presumably because
they fold or assemble incorrectly in the reductive intra-
cellular environment: indeed, dimerisation of heavy and
light chains and stabilisation by disulphide bonds often
occur with low e⁄ciency, if at all. To compensate for
this limitation, stabilised forms of antigen binding proteins
were developed (Fig. 1). Single chain fragment variable
region (scFv) constructs can exist inside the cell as contin-
uous polypeptides [21]. Recently, non-covalently associ-
ated Fv fragments (rFv) were functionally expressed inside
cells [22].
Some of these protein derivatives, also called ‘intrabod-
ies’, were used in eukaryotic cells to inactivate growth
factor receptors, oncoproteins and viral polypeptides
[23]. However, many of these in vitro-generated scFVs still
lose their activity fairly rapidly inside the cell, or cannot be
expressed at su⁄cient levels. To accommodate intracellu-
lar compartment conditions, strategies that use non-anti-
body-based structural frameworks to present the variable
segments of the antigen binding site were developed. For
example, peptides were embedded into the structural con-
Fig. 1. Proteins engineered for target recognition. IgG: structure of an antibody of the IgG class. Immunoglobulins formed via the adaptive immune re-
sponse consist of two light (VL and CL) and two heavy chains (VH and CH) which are covalently linked via disulphide bridges. The antigen binding
paratope is formed by the amino-terminal VL and VH domains which present hypervariable peptide segments; rFv: Fv fragment stabilised by rational
design; scFv: VH and VL domains covalently linked via peptides; scFvCL : VH, VL and CL domains covalently linked via peptides ; peptide aptamer:
variable peptides presented in the context of thioredoxin, lipocalin, or green £uorescent protein; RNA intramer: RNA aptamer in the context of RNA
expression cassettes.
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text of Escherichia coli thioredoxin [24], green £uorescent
protein [25], or members of the lipocalin protein family,
such as the retinol binding protein or the bilin binding
protein [26,27] (‘peptide aptamers’ and ‘lipocalins’, Fig.
1). Using yeast two-hybrid techniques, high a⁄nity inter-
actions for regulatory proteins such as cyclin-dependent
kinases [24,28,29] could be selected. Expression under
the control of the inducible Hsp70 promoter in transgenic
£ies resulted in a defective eye phenotype. These promising
results show that speci¢c protein inhibitors are potentially
capable of modulating the biological function of a protein
in vivo.
4. Intramers : intracellular nucleic acid aptamers
A potential alternative or supplement to these ap-
proaches are functional nucleic acids or aptamers. Ap-
tamers are speci¢c binders and potential inhibitors of pro-
teins that can be routinely isolated in vitro from nucleic
acid libraries of up to 1015 di¡erent molecules ^ the most
complex combinatorial libraries currently available. It is
becoming increasingly evident that aptamers can not
only be expressed inside cells, but also retain their function
and can alter the phenotype of a cell by modulating the
biological function of the targeted protein. Because of
their intracellular mode of action the term ‘intramer’ was
coined for these types of nucleic acid molecules. Intramers
can be easily modi¢ed and improved, for example, to spe-
ci¢cally distinguish between proteins that are highly ho-
mologous. Therefore, intramers allow precise investigation
of speci¢c molecules without also having to consider
closely related species. With respect to their functional
characteristics, such as binding a⁄nity or speci¢city, intra-
mers are at least as e⁄cient as monoclonal antibodies or
their derivatives.
In this review we will summarise the current status of
intramer research, focusing on intramers and their appli-
cations as novel tools for elucidating the function of pro-
teins by modulating their biological e¡ect within the con-
text of the living cell. We also present our views on the
potentials that may lie ahead for this promising new tech-
nology.
5. Intramers in HIV-1 research
Several groups have evolved aptamers against proteins
essential for HIV-1 replication, such as HIV-1 reverse
transcriptase [30^32], integrase [33], and the Rev protein
[34,35]. Among them the anti-HIV-1 Rev aptamers, which
were inserted into the full-length Rev-responsive element
in place of the Rev binding element (RBE) were found to
be functionally equivalent to the wild-type RBE in their
ability to promote Rev function in vivo [36]. Within the
viral genome Rev interacts with the RBE and is involved
in transport regulation of the viral RNA from the nucleus
to the cytoplasm. When expressed via RNA polymerase
III-dependent expression vectors, intracellular anti-Rev
aptamers e¡ectively inhibited HIV-1 production in cell
culture models [37]. Similar studies were carried out in
HeLa cells co-transfected with HIV-1 provirus (HXBvBgl)
and anti-Rev aptamer DNA. Here, too, virus formation
was speci¢cally inhibited [38]. Furthermore, no toxic ef-
fects of the intracellular aptamers were found. Considering
possible lifelong gene therapy treatment, strategies that are
solely based on functional RNAs may be superior to pro-
teins because of their considerably lower immunogenic
potential.
6. Intramers targeting nuclear proteins
While these examples showed that it is possible to block
viral proteins expressed in the nucleus, the following stud-
ies demonstrated that aptamers can also inhibit endoge-
nous nuclear targets in vivo, thus acting as e¡ective antag-
onists for nucleic acid binding proteins. For example,
Thomas et al. selected RNA aptamers against yeast
RNA polymerase II [39]. The isolated RNA aptamers ex-
hibit binding speci¢city for RNA polymerase II and do
not interact with RNA polymerases I or III. Interaction
studies showed that the aptamers preferentially bind the
two largest subunits of RNA polymerase II, B220 and
B150. Constitutive intracellular expression of the anti-
polymerase II aptamer under the control of the RNA
polymerase III promoter in yeast cells with an arti¢cially
reduced level of endogenous RNA polymerase II, resulted
in a cell growth defect that was not observed with non-
binding negative control RNAs [39].
More recently, a transgenic intramer-expressing animal
model characterised the e¡ect of intramer expression on
the phenotype of Drosophila melanogaster [40]. The target
for the in vitro aptamer selection was protein B52, a mem-
ber of the Drosophila SR protein family [41]. B52 partic-
ipates in the splicing of the pre-mRNA and in the selection
of alternative splice sites. For in vivo expression, a pen-
tameric aptamer construct was engineered which co-local-
ised with the B52 protein at its site of insertion in the
polytene chromosome. Although similar to the lethal phe-
notype in B52 knock-out £ies, expression of the multimer-
ic anti-B52 aptamer led only to a 50% reduction in the
development of adult transgenic £ies. The di¡erence in
survival rates compared to the genetic knock-out was ex-
plained by incomplete inhibition of the splice factor B52
by the intramer under equilibrium conditions in vivo.
While the absence of B52 is lethal, over-expression of
B52 can result in morphological defects such as absence of
salivary glands or missing bristles in adult animals. Intra-
mers expressed under the control of inducible promoters
with di¡erent RNA expression levels allowed a dose-de-
pendent investigation of intramer-mediated B52 counter-
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inhibition by monitoring these morphological markers in
adult animals. The phenotypic e¡ects resulting from over-
expression of B52 could be reversed in the presence of
certain levels of intramer, indicating that the intramers
were able to inhibit B52 function in vivo (Fig. 2).
Another interesting nuclear target is the transcription
factor NF-UB. This DNA binding heterodimeric protein
is an important activator of genes with functions related to
immunity, such as in£ammation and the synthesis of che-
mokines, interferons, MHC proteins, growth factors, and
cell adhesion molecules [42^45]. A small RNA aptamer
that recognised the NF-UB p50 subunit with nanomolar
a⁄nities and e¡ectively competed with DNA for binding
to the transcription factor was identi¢ed by in vitro selec-
tion [46]. This aptamer was also recently shown to bind
NF-UB p50 in yeast cells [47] by using a yeast three-hybrid
system [48].
7. Intramers that inhibit membrane and regulatory proteins
in the cytoplasm
The examples described above demonstrate that in vitro
selected RNA aptamers that target nuclear factors can be
functionally expressed in vivo. A signi¢cant advance in
intramer technology is the expression of intramers that
target non-nucleic acid binding proteins located in the
cytoplasm.
As a ¢rst step in this direction, Blind et al. [49] selected
RNA aptamers that recognise the cytoplasmic domain of
the L2 subunit of the human KLL2-integrin. The L2-integ-
rins are a family of heterodimeric transmembrane proteins
whose extracellular domains, by binding to extracellular
ligands, mediate the adhesion of leukocytes activated by
extracellular stimuli, such as MHC antigen complexes, in
immune and in£ammatory responses [50]. The cytoplasmic
domains of the integrin K and L chains are thought to be
involved in the transmission of signals from inside the cell
across the plasma membrane to the surface ^ a process
that is also referred to as ‘inside-out’ signalling [51]. Fig.
3 shows a model for the activation of KLL2-integrin
through the cytoplasmic L2-integrin domain [51,52]. PI
3-kinases are activated via signalling events originating
from cell surface receptors, such as the T-cell receptor
(TCR) or chemokine receptors. These enzymes then phos-
phorylate the phospholipid phosphatidyl inositol 4,5-bis-
phosphate to yield phosphatidylinositol 3,4,5-trisphos-
phate. This event recruits the cytoplasmic regulator pro-
tein cytohesin-1 (cyh1) to the cell membrane via its C-
terminal plextrin homology (PH) domain. Here, the Sec7
domain of cyh1 can interact with the cytoplasmic domain
of the L2-integrin chain, which in turn activates the extra-
cellular domain of the KLL2-integrin and induces binding
to intercellular adhesion molecule 1 (ICAM-1).
To achieve T7 RNA polymerase-controlled expression
of aptamers in the cytoplasm of leukocytes we used an
intramer expression system based on the infection of
T-cells with recombinant vaccinia viruses [49]. Since the
complete life cycle of these poxviruses, from DNA repli-
cation to protein translation, occurs in the cytoplasm of
the host cells [53], the transcription of the intramers will
take place exclusively in the same compartment as the
location of the target protein. Furthermore, vaccinia vi-
ruses exhibit a broad host spectrum and thus are ideal
vectors to infect KLL2-integrin-bearing T-cells. The paren-
tal aptamer sequences were cloned into a T7 RNA poly-
merase-dependent RNA expression cassette based on a
modi¢ed version of a highly e¡ective transcription system,
in a vector called vTR [54]. Double infection with two
recombinant vaccinia viruses, one (vTR) carrying the in-
tramer-encoding DNA under the control of the T7 pro-
moter, the other (vT7) encoding the T7 RNA polymerase,
led to high levels of intramers in the cytoplasm. In the
expression constructs, the aptamer RNA is £anked by
additional stem-loop structures at the 5P- and 3P-ends.
Fig. 2. In vivo expression of aptamers suppresses the phenotypes caused
by B52 over-expression. (A) The larval salivary gland phenotype. Left :
over-expression of B52 results in 100% undeveloped larval salivary
glands. Right: co-expression of the anti-B52 aptamer construct rescues
the phenotype resulting from B52 over-expression ^ salivary glands are
100% developed with near normal morphology. (B) The morphological
marker of bristle development. Left : nearly no bristles are observed
when B52 is overproduced. Right: bristles develop with nearly normal
density in the presence of the anti-B52 pentameric intramer.
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Fig. 3. Model for the activation of KLL2-integrins and the activation of ADP-ribosylation factors (ARF) by the cytoplasmic regulator protein cytohesin-
1. Stimulation of leukocytes by cell surface receptors (e.g. cytokine receptors or the T-cell receptor, TCR) leads to the activation of phosphatidylinositol
phospholipase C (PI-PLC), which catalyses the phosphorylation of phosphatidylinositol bisphosphate. The regulatory protein cytohesin-1 is recruited to
the cytoplasmic membrane via binding to phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3). Interaction of the Sec7 domain with the L2-integrin
subunit is thought to activate the LFA-1 integrin, which subsequently binds to its extracellular ligand. This process is also known as inside-out signal-
ling. A second activity of the Sec7 domain is stimulation of the GDP/GTP exchange, which activates small GTPases. In vitro data suggest that cytohe-
sin-1 is a GDP/GTP exchange factor of the ARF family of GTPases, which are involved in the control of membrane-associated events or the remodel-
ling of the cytoskeleton.
Fig. 4. Scheme for the aptamer expression cassette TR and the vaccinia virus-based cytoplasmic RNA expression system. (A) The aptamer-encoding
DNA was inserted between the stabilising 5P-stem loop and the 3P-hairpin that acts as the Tx terminator signal for T7 RNA polymerase. Both sequen-
ces serve to stabilise the intramer transcripts. The binding behaviour of the aptamer is maintained when inserted into this new sequence context.
(B) Scheme for the double infection of Jurkat E6 cells with two recombinant vaccinia viruses, one encoding T7 RNA polymerase (vT7), the other en-
coding the intramer (vTR). After virus entry, excretion and replication of viral DNA, T7 RNA polymerase is expressed. The enzyme then synthesises
intramer RNA in the cytoplasm (blue) from the transcription units controlled by the T7 promoter integrated into the genome of the virus vTR.
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These motifs serve as stabilising elements, ensure mainte-
nance of aptamer functionality and lead to correct termi-
nation of the RNA transcripts. The intramer RNA should
not undergo signi¢cant further RNA processing or asso-
ciation with the ribosomal translation machinery [54] (Fig.
4). Expression in T-lymphocytes revealed that anti-L2 in-
tramers were able to speci¢cally inhibit KLL2-integrin-
mediated phorbol ester-stimulated cell adhesion to immo-
bilised ICAM-1 [49]. This study established intramers as
powerful tools for modulating the biological function of
cytoplasmic membrane protein domains, leading to highly
speci¢c cellular e¡ects.
In a more recent investigation, Mayer et al. applied the
same technology to gain new biological information [55].
This time, the target for an in vitro aptamer selection was
cyh1 itself. The goal was to probe the function of the Sec7
domain of cyh1, which is thought to act as a small guanine
nucleotide exchange factor (GEF) on ARF GTPases (Fig.
3). ARF GTPases and their regulatory proteins have been
implicated in the control of vesicle transport and cell ad-
hesion. Two main classes of positive regulatory elements
for ARF have been discovered so far, namely the large
Sec7/Gea, and the small cytohesin/ARNO families. These
proteins harbour GEF activity exerted by the common
Sec7 domain. The availability of a speci¢c inhibitor, the
fungal metabolite brefeldin A, enabled the involvement of
the large GEFs in vesicle transport to be documented.
However, the biological roles of the small GEFs have
remained controversial due to the lack of equivalent tools
[56,57]. Using cyh1 immobilised on a Sepharose support,
Mayer et al. obtained an aptamer, called M69, that binds
the Sec7 domain of cyh1 and inhibits its GEF activity,
thus preventing ARF activation in vitro. In contrast, the
Sec7 domain of Gea2, a member of the large GEF family,
is not inhibited. This in vitro function of M69 correlated
with e¡ects in vivo: when expressed in the cytoplasm of
T-cells, M69 aptamers speci¢cally led to a cell-spreading
de¢ciency accompanied by dramatic reorganisation of
F-actin distribution when the cells adhered to ¢bronectin
(Fig. 5). Important proof that this in vivo e¡ect clearly
resulted from the aptamer’s inhibitory activity character-
ised in vitro came from the same e¡ect observed after
dominant negative expression of a GEF-de¢cient
cyh1(E157K) mutant [55]. Such a clear correlation be-
tween in vitro and cytoplasmic functions of an inhibitory
intramer had never been demonstrated before. Nor was it
known before that a previously observed cell-spreading
de¢ciency [58] can be linked to rearrangement of the actin
cytoskeleton resulting directly from inhibition of the GEF
activity of the cyh1 Sec7 domain.
This work added an entirely new quality to studying the
biological functions of proteins or protein domains in
vivo: the intramer approach has the capacity to inhibit a
function without over-expressing a normal or aberrant
Fig. 5. Cytoplasmic expression of an aptamer that inhibits the GEF function exerted by the Sec7 domain of cyh1, a member of the class of small
(6 50 kDa) GEFs. For this class of GEFs, no inhibitors have been previously identi¢ed. (A) Intramer expression speci¢cally induces considerable reor-
ganisation of F-actin distribution (vT7/vTR-M69, middle) when the human T-cells were attached to ¢bronectin. No signi¢cant di¡erence to wild-type
cells (E6 Jurkat, left) was found when a non-cognate intramer was expressed at similar levels (vT7/vTR-ML1, right). Actin distribution was visualised
by TRITC phalloidin that recognises F-actin. (B) Dominant negative over-expression of a GEF-de¢cient mutant of cyh1 (cyh1(E157K) mutant; left)
leads to a phenotype indistinguishable from that obtained by expressing the GEF inhibitory intramer M69 (vT7/vM69; middle). The right panel shows
the wild-type phenotype obtained after expression of cyh1 fused to an immunoglobulin tag. Visualisation was by confocal microscopy.
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protein, thereby avoiding possible perturbance of a system
by elevated expression levels. The e⁄cient combinatorial
selection of an inhibitor, combined with the ability to ex-
press it readily without loss of function in the context of
the living cell, and in the relevant cellular compartment,
represents a new paradigm for developing novel ap-
proaches to gaining information about individual proteins
or sub-domains in the context of their natural expression
and location.
Several very promising aptameric inhibitors targeting
intracellular regulatory proteins with impressive speci¢city
are now available. The most e⁄cient aptamers are capable
of reliably distinguishing polypeptides with 96% homology
[59]. Seiwert et al. [60] recently described RNA aptamers
that can selectively recognise the extracellularly regulated
kinase 2 (ERK2), a member of the class of mitogen-acti-
vated protein kinases (MAPK), with high picomolar a⁄n-
ity. In vitro, the aptamers inhibit the phosphorylation ac-
tivity of ERK2, presumably by competing with the ATP
cofactor. The speci¢city of these aptamers is high: only
phosphorylation by ERK1 and ERK2, but not by the
related Jun N-terminal kinase or p38 MAPK, is inhibited.
Taken together, all these examples show that intramers
provide a potential means to analyse the function of
closely related proteins in a very focused manner. Further-
more, it was recently shown that the very robust in vitro
selection process could also be carried out in an auto-
mated fashion [61]. This advancement allows complete in
vitro selections to be performed within a couple of days,
instead of several weeks as required by current manual
protocols. Thus, it will be possible in the near future not
only to generate aptamers for a huge number of targets
considerably faster, but to use them directly in cellular
systems.
8. Targeting speci¢c cellular compartments
The vaccinia virus-based intramer expression system
was used as an initial approach to ensure intramer pro-
duction directly in the relevant cellular compartment.
However, for general, more widely applicable use this ex-
pression system may have certain limitations. For exam-
ple, it would be highly desirable to have expression sys-
tems that use inducible endogenous promoters producing
intramers containing RNA signals designed to automati-
cally target the intramer into the cellular compartment
harbouring its cognate ligand. For approaches that em-
ploy ribozymes to control gene expression, intracellular
RNA expression systems have been developed. In most
cases these transcription systems use retroviral or polymer-
ase III-controlled promoters [15,62,63]. The anti-Rev ap-
tamers discussed above were expressed via U6 and tRNA
constructs in cell culture [37]. The problem one may have
to face when using these approaches is that transcription
yields of 103^104 molecules per cell may be too low to
exert detectable e¡ects. In some cases the addition of se-
quences from natural genes of small RNA molecules, such
as U6 snRNA or tRNAmet, may lead to 10-fold higher
expression levels and sometimes also to increased stability
[37].
One can imagine a number of approaches that may be
used to direct intramers to the cytoplasm or facilitate their
localisation to other cellular compartments. Hamm et al.
[64] used antibodies speci¢c for the nuclear export signal
(NES) of the HIV-1 Rev protein to select RNA mimics of
the NES by in vitro selection. When injected into the
nucleus of Xenopus oocytes, the RNA mimics were either
exported actively, or blocked Rev-dependent export of a
reporter RNA. In addition, they inhibited the cap-depen-
dent U1 snRNA export in Xenopus oocytes in a manner
similar to NES^peptide conjugates. Recently it was shown
that the inhibition of Rev-mediated export results from the
RNA mimics binding to the NES recognition domain of
the exportin CRM1, the export receptor for leucine-rich
NES sequences [65]. When fused to an intramer sequence
that targets a cytoplasmic protein, such ‘export aptamers’
may serve as nucleic acid-based exportin ligands for deliv-
ering an intramer to its cytoplasmic target through the
nuclear pore complex.
Grimm et al. [66] also isolated RNAs from combinato-
rial RNA libraries that are exported from nuclei of Xen-
opus oocytes. When fused to non-selected RNAs, the se-
lected sequences acted like a NES in promoting e⁄cient
export of RNAs that are otherwise not exported. How-
ever, these chimeric RNAs, unlike the selected RNAs,
were not exported in the presence of matrix protein indi-
cating that the non-selected sequences can cause retention
of the selected RNA sequences under certain conditions.
RNAs that are actively imported into the nucleus have
also been isolated [67]. It was shown that import of a class
of in vivo selected RNAs was distinct from that of U6
RNA.
9. Conclusion
To develop highly speci¢c drugs with minimal side ef-
fects it will become increasingly important to know the
cellular and molecular mechanisms that lead to a partic-
ular dysfunction. Molecular engineering based on combi-
natorial methods has led to a wide range of functionally
active protein, peptide, or RNA molecules that can be
used to elucidate the biological activity of intracellular
proteins. Methodologies that apply intracellular inhibitors
may also be a highly e⁄cient means of validating potential
pharmaceutical targets as well as rapidly ¢nding out
whether agonistic or antagonistic mechanisms can a¡ect
a protein. The advantage of inhibitors based on biopoly-
mers is that most of them can be easily and rapidly iden-
ti¢ed by in vitro techniques. Due to their cellular compat-
ibility RNA intramers may be particularly suited for
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acting as e⁄cient intracellular antagonists for a large num-
ber of potential targets.
Intramers can easily be tailored for their use in vivo by
adding additional functions, such as enhanced stability,
and signals for cellular localisation. Where appropriate,
intramers may be inserted into appropriate vectors where
intramer expression simply requires the cell’s own tran-
scription machinery. When expressed in human cells, in-
tramers can speci¢cally bind and potentially inhibit the
targeted molecule, making them highly e¡ective tools for
dissecting an intracellular protein, protein domain or sub-
domain. Because of their high a⁄nities and speci¢cities,
intramers are excellently suited to speci¢cally inhibit key
events in signal transduction, cell growth, transcription,
and many other intracellular processes.
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